In vivo affinity and target engagement in skin and blood in a first‐time‐in‐human study of an anti‐oncostatin M monoclonal antibody

• Published in: British journal of clinical pharmacology Vol. 84; no. 10; pp. 2280 - 2291
• Main Authors: Reid, Juliet, Zamuner, Stefano, Edwards, Ken, Rumley, Sally‐Anne, Nevin, Katherine, Feeney, Maria, Zecchin, Chiara, Fernando, Disala, Wisniacki, Nicolas
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.10.2018
• Subjects: Adult; affinity; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacokinetics; Area Under Curve; Blister - drug therapy; Blister - etiology; Blister - immunology; Blister - pathology; Double-Blind Method; Female; first‐time‐in‐human; GSK2330811; Healthy Volunteers; Humans; Injections, Subcutaneous; Male; Middle Aged; Models, Biological; oncostatin M; Oncostatin M - antagonists & inhibitors; Oncostatin M - immunology; Original; Placebos - administration & dosage; Placebos - adverse effects; Skin - drug effects; Skin - immunology; Skin - pathology; Suction - adverse effects; target engagement; GSK2330811; oncostatin M; target engagement; first-time-in-human; affinity

Aims The oncostatin M (OSM) pathway drives fibrosis, inflammation and vasculopathy, and is a potential therapeutic target for inflammatory and fibrotic diseases. The aim of this first‐time‐in‐human experimental medicine study was to assess the safety, tolerability, pharmacokinetics and target engage...